Haemonetics (HAE)
Market Price (11/14/2025): $73.91 | Market Cap: $3.5 BilSector: Health Care | Industry: Health Care Supplies
Haemonetics (HAE)
Market Price (11/14/2025): $73.91Market Cap: $3.5 BilSector: Health CareIndustry: Health Care Supplies
Investment Highlights
Why It Matters
Which of these 2 stories sounds closer for this stock?
1. Generates cash flow
The stock generated 4% or more of the share price (called cash flow yield), and shows moderate 10-15% or more growth.
2. Riding a trend
Think Tesla during the pandemic of 2020 when EVs were riding a cultural high, or Nvidia in the current AI boom, or even Figma. These companies don’t have enough yield, or, enough growth, or both - however - they are riding a trend. They have momentum. These can be more volatile - they don’t have the floor of strong cash flow
| Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 22%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 19% | Weak multi-year price returns2Y Excs Rtn is -69%, 3Y Excs Rtn is -88% | Weak revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is -2.5%, Rev Chg QQuarterly Revenue Change % is -5.3% |
| Attractive yieldFCF Yield is 7.3% | ||
| Megatrend and thematic driversMegatrends include Aging Population & Chronic Disease, Digital Health & Telemedicine, and Automation & Robotics. Themes include Geriatric Care, Show more. |
| Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 22%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 19% |
| Attractive yieldFCF Yield is 7.3% |
| Megatrend and thematic driversMegatrends include Aging Population & Chronic Disease, Digital Health & Telemedicine, and Automation & Robotics. Themes include Geriatric Care, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -69%, 3Y Excs Rtn is -88% |
| Weak revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is -2.5%, Rev Chg QQuarterly Revenue Change % is -5.3% |
Market Valuation & Key Metrics
HAE Stock
Why The Stock Moved
Qualitative Assessment
AI Generated Analysis | Feedback
Here are the key points explaining the approximate -0.2% movement of Haemonetics (HAE) stock from July 31, 2025, to November 14, 2025:
1. Mixed Analyst Sentiment and Price Target Reductions: Throughout the period, several analyst firms adjusted their outlook on Haemonetics. For instance, on August 8, 2025, J.P. Morgan downgraded the stock from "Buy" to "Hold" and reduced its price target from $85 to $62. Similarly, on October 7, 2025, Citigroup lowered its price target from $78 to $64, while maintaining a "Strong Buy" rating. These cautious revisions from analysts likely weighed on investor sentiment and limited upward movement or contributed to slight declines.
2. Reported Revenue Decline Due to Portfolio Transition: Haemonetics' second-quarter fiscal 2026 results, released on November 6, 2025, indicated a reported revenue decline of 5.3% year-over-year to $327.3 million. This decline was primarily attributed to strategic portfolio transitions, specifically the divestiture of its Whole Blood business. While the company emphasized strong organic revenue growth of 9.4% excluding this impact, the overall reported revenue decrease may have created some investor apprehension, contributing to a tempered stock performance over the period.
Stock Movement Drivers
Return vs. Risk
Price Returns Compared
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| HAE Return | 3% | -55% | 48% | 9% | -9% | -5% | -36% |
| Peers Return | 61% | 25% | -27% | 5% | -17% | -21% | 0% |
| S&P 500 Return | 16% | 27% | -19% | 24% | 23% | 15% | 109% |
Monthly Win Rates [3] | |||||||
| HAE Win Rate | 50% | 42% | 67% | 58% | 42% | 30% | |
| Peers Win Rate | 58% | 62% | 47% | 57% | 40% | 44% | |
| S&P 500 Win Rate | 58% | 75% | 42% | 67% | 75% | 70% | |
Max Drawdowns [4] | |||||||
| HAE Max Drawdown | -35% | -58% | -17% | -8% | -17% | -39% | |
| Peers Max Drawdown | -32% | -4% | -41% | -18% | -31% | -37% | |
| S&P 500 Max Drawdown | -31% | -1% | -25% | -1% | -2% | -15% | |
[1] Cumulative total returns since the beginning of 2020
[2] Peers: MMSI, CNMD, STAA, IART, WST. See HAE Returns vs. Peers.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2025 data is for the year up to 11/13/2025 (YTD)
How Low Can It Go
| Event | HAE | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -68.6% | -25.4% |
| % Gain to Breakeven | 218.7% | 34.1% |
| Time to Breakeven | Not Fully Recovered days | 464 days |
| 2020 Covid Pandemic | ||
| % Loss | -39.0% | -33.9% |
| % Gain to Breakeven | 63.9% | 51.3% |
| Time to Breakeven | 294 days | 148 days |
| 2018 Correction | ||
| % Loss | -29.9% | -19.8% |
| % Gain to Breakeven | 42.7% | 24.7% |
| Time to Breakeven | 63 days | 120 days |
| 2008 Global Financial Crisis | ||
| % Loss | -25.3% | -56.8% |
| % Gain to Breakeven | 33.9% | 131.3% |
| Time to Breakeven | 707 days | 1480 days |
Compare to MMSI, CNMD, STAA, IART, WST
In The Past
Haemonetics's stock fell -68.6% during the 2022 Inflation Shock from a high on 2/8/2021. A -68.6% loss requires a 218.7% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth over time.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
Latest Trefis Analyses
Trade Ideas
Select past ideas related to HAE. For more, see Trefis Trade Ideas.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 10312025 | GDRX | GoodRx | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | -9.2% | -9.2% | -10.1% |
| 10312025 | DXCM | DexCom | Monopoly | MY | Getting CheaperMonopoly-Like with P/S DeclineLarge cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple | 2.4% | 2.4% | -5.8% |
| 10242025 | ACHC | Acadia Healthcare | Dip Buy | DB | P/E OPMDip Buy with Low PE and High MarginBuying dips for companies with tame PE and meaningfully high operating margin | -25.6% | -25.6% | -25.6% |
| 10102025 | PBH | Prestige Consumer Healthcare | Dip Buy | DB | P/E OPMDip Buy with Low PE and High MarginBuying dips for companies with tame PE and meaningfully high operating margin | -0.8% | -0.8% | -1.9% |
| 10032025 | REGN | Regeneron Pharmaceuticals | Dip Buy | DB | P/E OPMDip Buy with Low PE and High MarginBuying dips for companies with tame PE and meaningfully high operating margin | 13.6% | 13.6% | -7.0% |
| 08312025 | HAE | Haemonetics | Dip Buy | DB | P/E OPMDip Buy with Low PE and High MarginBuying dips for companies with tame PE and meaningfully high operating margin | 34.1% | 34.1% | -12.6% |
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 10312025 | GDRX | GoodRx | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | -9.2% | -9.2% | -10.1% |
| 10312025 | DXCM | DexCom | Monopoly | MY | Getting CheaperMonopoly-Like with P/S DeclineLarge cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple | 2.4% | 2.4% | -5.8% |
| 10242025 | ACHC | Acadia Healthcare | Dip Buy | DB | P/E OPMDip Buy with Low PE and High MarginBuying dips for companies with tame PE and meaningfully high operating margin | -25.6% | -25.6% | -25.6% |
| 10102025 | PBH | Prestige Consumer Healthcare | Dip Buy | DB | P/E OPMDip Buy with Low PE and High MarginBuying dips for companies with tame PE and meaningfully high operating margin | -0.8% | -0.8% | -1.9% |
| 10032025 | REGN | Regeneron Pharmaceuticals | Dip Buy | DB | P/E OPMDip Buy with Low PE and High MarginBuying dips for companies with tame PE and meaningfully high operating margin | 13.6% | 13.6% | -7.0% |
| 08312025 | HAE | Haemonetics | Dip Buy | DB | P/E OPMDip Buy with Low PE and High MarginBuying dips for companies with tame PE and meaningfully high operating margin | 34.1% | 34.1% | -12.6% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons for Haemonetics
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 58.59 |
| Mkt Cap | 2.4 |
| Rev LTM | 1,412 |
| Op Inc LTM | 143 |
| FCF LTM | 176 |
| FCF 3Y Avg | 132 |
| CFO LTM | 218 |
| CFO 3Y Avg | 166 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 4.8% |
| Rev Chg 3Y Avg | 4.5% |
| Rev Chg Q | 6.1% |
| QoQ Delta Rev Chg LTM | 1.5% |
| Op Mgn LTM | 10.1% |
| Op Mgn 3Y Avg | 10.5% |
| QoQ Delta Op Mgn LTM | -0.0% |
| CFO/Rev LTM | 15.3% |
| CFO/Rev 3Y Avg | 12.4% |
| FCF/Rev LTM | 11.8% |
| FCF/Rev 3Y Avg | 9.9% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 2.4 |
| P/S | 3.1 |
| P/EBIT | 12.9 |
| P/E | 20.9 |
| P/CFO | 11.3 |
| Total Yield | 2.5% |
| Dividend Yield | 0.0% |
| FCF Yield 3Y Avg | 2.3% |
| D/E | 0.3 |
| Net D/E | 0.2 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | -0.3% |
| 3M Rtn | -3.2% |
| 6M Rtn | -0.5% |
| 12M Rtn | -20.9% |
| 3Y Rtn | -27.3% |
| 1M Excs Rtn | 0.2% |
| 3M Excs Rtn | -7.5% |
| 6M Excs Rtn | -14.3% |
| 12M Excs Rtn | -31.0% |
| 3Y Excs Rtn | -103.0% |
Comparison Analyses
Returns Analyses
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 11/6/2025 | 32.3% | ||
| 8/7/2025 | -26.6% | -28.9% | -28.2% |
| 5/8/2025 | 5.9% | 6.8% | 9.7% |
| 2/6/2025 | -11.6% | -13.9% | -3.6% |
| 11/7/2024 | 10.7% | 17.4% | 3.9% |
| 8/8/2024 | -10.8% | -14.6% | -14.6% |
| 5/9/2024 | -0.7% | 3.5% | -8.2% |
| 2/8/2024 | 1.3% | -7.6% | 3.2% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 13 | 12 | 13 |
| # Negative | 10 | 11 | 10 |
| Median Positive | 8.9% | 7.3% | 6.3% |
| Median Negative | -8.8% | -7.3% | -8.2% |
| Max Positive | 32.3% | 23.8% | 33.1% |
| Max Negative | -26.6% | -28.9% | -28.2% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 9302025 | 11062025 | 10-Q 9/27/2025 |
| 6302025 | 8072025 | 10-Q 6/28/2025 |
| 3312025 | 5212025 | 10-K 3/29/2025 |
| 12312024 | 2062025 | 10-Q 12/28/2024 |
| 9302024 | 11072024 | 10-Q 9/28/2024 |
| 6302024 | 8082024 | 10-Q 6/29/2024 |
| 3312024 | 5202024 | 10-K 3/30/2024 |
| 12312023 | 2082024 | 10-Q 12/30/2023 |
| 9302023 | 11022023 | 10-Q 9/30/2023 |
| 6302023 | 8082023 | 10-Q 7/1/2023 |
| 3312023 | 5222023 | 10-K 4/1/2023 |
| 12312022 | 2072023 | 10-Q 12/31/2022 |
| 9302022 | 11082022 | 10-Q 10/1/2022 |
| 6302022 | 8102022 | 10-Q 7/2/2022 |
| 3312022 | 5252022 | 10-K 4/2/2022 |
| 12312021 | 2082022 | 10-Q 1/1/2022 |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |